Key points are not available for this paper at this time.
Design
Editorial
Answers are grounded in this paper and cite their sources.
Discusses the potential role of ciraparantag as a universal reversal agent for direct oral anticoagulants.
This editorial refers to ‘Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects’ by J. Ansell et al., doi:10.1093/eurheartj/ehab637. Direct oral anticoagulants (DOACs) include dabigatran, which inhibits thrombin, and apixaban, edoxaban, and rivaroxaban, which inhibit factor Xa (FXa). Use of the DOACs increased when guidelines gave preference to them over vitamin K antagonists (VKAs) such as warfarin for stroke prevention in patients with non-valvular atrial fibrillation and for treatment of venous thrombo-embolism.1–3 Of the DOACs, apixaban and rivaroxaban are the most widely used.4 Although the DOACs are associated with less serious bleeding than VKAs, particularly less intracranial haemorrhage, bleeding remains the major side effect of the DOACs. Consequently, agents that rapidly reverse the anticoagulant effects of the DOACs could streamline management and improve outcomes of patients presenting with serious bleeding or requiring urgent interventions or surgery. Idarucizumab, an antibody fragment that...
No takes yet. Share an insight, caveat, or question.
Chan et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: